Show simple item record

dc.contributor.authorŞenkardeş, Sevil
dc.contributor.authorÖzaydın, Tuğçe
dc.contributor.authorUğurlu, Timuçin
dc.contributor.authorKüçükgüzel, Ş. Güniz
dc.date.accessioned2018-02-22T21:12:34Z
dc.date.available2018-02-22T21:12:34Z
dc.date.issued2017
dc.identifier.urihttp://hdl.handle.net/11424/6306
dc.description.abstractThe aim of the present study was to develop and validate a High-Performance Liquid Chromatography (HPLC) method for the determination of lisinopril and gliclazide. The method was developed on Zorbax C8 analytical column (4.6x250 mm; 5μm) by isocratic elution with a flow rate of 1.0 mL/min and injection volume of 25 μl. The mobile phase composition was methanol:water (65:35 v/v, pH adjusted to 3.0 triethylamineorthophosphoric acid buffer) and the retention time was found to be 2.883 and 7.456 min for lisinopril and gliclazide, respectively. The developed method was found to be linear in the concentration range of 5-20 μg/mL for lisinopril and 15-60 μg/mL for gliclazide. The method was validated for linearity, accuracy, precision, LOD and LOQ. This developed procedure was succesfully applied conveniently for the analysis of lisinopril and gliclazide in pharmaceutical preparations.en_US
dc.language.isoengen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCombined dosage forms, gliclazide, lisinopril, RPHPLC, method validationen_US
dc.titleDevelopment and validation of a reversed-phase HPLC method for the determination of lisinopril and gliclazide in pharmaceuticalsen_US
dc.typearticleen_US
dc.contributor.authorIDTR49974en_US
dc.contributor.authorIDTR172084en_US
dc.relation.journalMarmara Pharmaceutical Journalen_US
dc.identifier.volume21en_US
dc.identifier.issue2en_US
dc.identifier.startpage338en_US
dc.identifier.endpage344en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record